Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Nadira Ruzehaji, Camelia Frantz, Matthieu Ponsoye, Jerome Avouac, Sonia Pezet, Thomas Guilbert, Jean-Michel Luccarini, Pierre Broqua, Jean-Louis Junien, Yannick Allanore, Nadira Ruzehaji, Camelia Frantz, Matthieu Ponsoye, Jerome Avouac, Sonia Pezet, Thomas Guilbert, Jean-Michel Luccarini, Pierre Broqua, Jean-Louis Junien, Yannick Allanore
Abstract
Background: The pathogenesis of systemic sclerosis (SSc) involves a distinctive triad of autoimmune, vascular and inflammatory alterations resulting in fibrosis. Evidence suggests that peroxisome proliferator-activated receptors (PPARs) play an important role in SSc-related fibrosis and their agonists may become effective therapeutic targets.
Objective: To determine the expression of PPARs in human fibrotic skin and investigate the effects of IVA337, a pan PPAR agonist, in in vitro and in vivo models of fibrosis.
Methods: The antifibrotic effects of IVA337 were studied using a bleomycin-induced mouse model of dermal fibrosis. The in vivo effect of IVA337 on wound closure and inflammation were studied using an excisional model of wound healing.
Results: Low levels of PPARα and PPARγ were detected in the skin of patients with SSc compared with controls. In mice, IVA337 was associated with decreased extracellular matrix (ECM) deposition and reduced expression of phosphorylated SMAD2/3-intracellular effector of transforming growth factor (TGF)-β1. Although the antifibrotic effect of pan PPAR was similar to that of PPARγ agonist alone, a significant downregulation of several markers of inflammation was associated with IVA337. Despite its anti-inflammatory and antifibrotic properties, IVA337 did not interfere with wound closure. In vitro effects of IVA337 included attenuation of transcription of ECM genes and alteration of canonical and non-canonical TGF-β signalling pathways.
Conclusions: These findings indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc.
Keywords: Fibroblasts; Inflammation; Systemic Sclerosis.
Conflict of interest statement
YA consulted and received research funding from Actelion, Bayer, Biogen Idec, BMS, Genentech/Roche, Inventiva, Medac, Pfizer, Sanofi/Genzyme, Servier and UCB. YA is a member of the advisory board for the upcoming clinical study of IVA337 in systemic sclerosis. J-ML, PB and J-LJ are employed by Inventiva.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Figures
References
- Allanore Y, Distler O. Systemic sclerosis in 2014: advances in cohort enrichment shape future of trial design. Nat Rev Rheumatol 2015;11:72–4. 10.1038/nrrheum.2014.222
- Elhai M, Avouac J, Kahan A, et al. . Systemic sclerosis: recent insights. Joint Bone Spine 2015;82:148–53. 10.1016/j.jbspin.2014.10.010
- Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989–2003. 10.1056/NEJMra0806188
- Ho YY, Lagares D, Tager AM, et al. . Fibrosis—a lethal component of systemic sclerosis. Nat Rev Rheumatol 2014;10:390–402. 10.1038/nrrheum.2014.53
- Lafyatis R. Transforming growth factor β-at the centre of systemic sclerosis. Nat Rev Rheumatol 2014;10:706–19. 10.1038/nrrheum.2014.137
- Palumbo-Zerr K, Zerr P, Distler A, et al. . Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat Med 2015;21:150–8. 10.1038/nm.3777
- Ghosh AK, Bhattacharyya S, Wei J, et al. . Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 2009;23:2968–77. 10.1096/fj.08-128736
- Still K, Grabowski P, Mackie I, et al. . The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 2008;83:285–92. 10.1007/s00223-008-9175-9
- Wei J, Ghosh AK, Sargent JL, et al. . PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS ONE 2010;5:e13778 10.1371/journal.pone.0013778
- Samah M, El-Aidy Ael R, Tawfik MK, et al. . Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol 2012;689:186–93. 10.1016/j.ejphar.2012.05.026
- Galuppo M, Di Paola R, Mazzon E, et al. . GW0742, a high affinity PPAR-beta/delta agonist reduces lung inflammation induced by bleomycin instillation in mice. Int J Immunopathol Pharmacol 2010;23:1033–46.
- Aoki Y, Maeno T, Aoyagi K, et al. . Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009;77:311–19. 10.1159/000168676
- Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12:181–95. 10.1038/nrc3214
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71. 10.1056/NEJMoa072761
- LeRoy EC, Black C, Fleischmajer R, et al. . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
- Avouac J, Elhai M, Tomcik M, et al. . Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2013;72:1089–98. 10.1136/annrheumdis-2012-201759
- Beyer C, Schett G, Distler O, et al. . Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62:2831–44. 10.1002/art.27647
- Ruzehaji N, Kopecki Z, Melville E, et al. . Attenuation of flightless I improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes. Diabetologia 2014;57:402–12. 10.1007/s00125-013-3107-6
- Desallais L, Avouac J, Frechet M, et al. . Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014;16:R157 10.1186/ar4672
- Avouac J, Palumbo-Zerr K, Ruzehaji N, et al. . The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor beta and Contributes to the Development of Experimental Dermal Fibrosis. Arthritis Rheumatol 2014;66:3140–50. 10.1002/art.38819
- Ruzehaji N, Avouac J, Elhai M, et al. . Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis. Arthritis Res Ther 2015;17:145 10.1186/s13075-015-0659-5
- Ruzehaji N, Mills SJ, Melville E, et al. . The influence of Flightless I on Toll-like-receptor-mediated inflammation in a murine model of diabetic wound healing. Biomed Res Int 2013;2013:389792 10.1155/2013/389792
- Lei N, Franken L, Ruzehaji N, et al. . Flightless, secreted through a late endosome/lysosome pathway, binds LPS and dampens cytokine secretion. J Cell Sci 2012;125(Pt 18):4288–96. 10.1242/jcs.099507
- Lupatov AY, Vdovin AS, Vakhrushev IV, et al. . Comparative analysis of the expression of surface markers on fibroblasts and fibroblast-like cells isolated from different human tissues. Bull Exp Biol Med 2015;158:537–43. 10.1007/s10517-015-2803-2
- Pfisterer K, Lipnik KM, Hofer E, et al. . CD90+ human dermal stromal cells are potent inducers of FoxP3(+) regulatory T cells. J Invest Dermatol 2015;135:130–41. 10.1038/jid.2014.309
- Huang J, Beyer C, Palumbo-Zerr K, et al. . Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2016;75:883–90.
- Mastrofrancesco A, Kovacs D, Sarra M, et al. . Preclinical studies of a specific PPARgamma modulator in the control of skin inflammation. J Invest Dermatol 2014;134:1001–11. 10.1038/jid.2013.448
- Wu M, Melichian DS, Chang E, et al. . Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009;174:519–33. 10.2353/ajpath.2009.080574
- Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly 2002;132:83–91.
- Martin P. Wound healing–aiming for perfect skin regeneration. Science 1997;276:75–81. 10.1126/science.276.5309.75
- Gurtner GC, Werner S, Barrandon Y, et al. . Wound repair and regeneration. Nature 2008;453:314–21. 10.1038/nature07039
- Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. Growth Factors 2011;29:196–202. 10.3109/08977194.2011.595714
- Jeon KI, Kulkarni A, Woeller CF, et al. . Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation. Am J Pathol 2014;184:1429–45. 10.1016/j.ajpath.2014.01.026
- Yessoufou A, Wahli W. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly 2010;140:w13071 10.4414/smw.2010.13071
- Okada-Iwabu M, Yamauchi T, Iwabu M, et al. . A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013;503:493–9. 10.1038/nature12656
- Gao Q, Jia Y, Yang G, et al. . PPARalpha-deficient Ob/Ob obese mice become more obese and manifest severe hepatic steatosis due to decreased fatty acid oxidation. Am J Pathol 2015;185:1396–408. 10.1016/j.ajpath.2015.01.018
Source: PubMed